{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=86", "query": { "condition": "Lymphoid", "page": 86 }, "page_size": 10 }, "pagination": { "page": 86, "page_size": 10, "total_count": 3083, "total_pages": 309, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=87&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=85&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T09:32:28.853Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01589302", "title": "PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prolymphocytic Leukemia", "Recurrent Small Lymphocytic Lymphoma", "Refractory/Relapsed Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "ibrutinib", "type": "DRUG" }, { "name": "Correlative laboratory samples", "type": "OTHER" }, { "name": "quality of life assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kami Maddocks, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2012-05-21", "completion_date": "2026-10-31", "has_results": true, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-11-14T09:32:28.853Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01589302" }, { "nct_id": "NCT01805037", "title": "Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Grade III Lymphomatoid Granulomatosis", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Contiguous Stage II Adult Burkitt Lymphoma", "Contiguous Stage II Adult Diffuse Large Cell Lymphoma", "Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Contiguous Stage II Adult Lymphoblastic Lymphoma", "Contiguous Stage II Grade 1 Follicular Lymphoma", "Contiguous Stage II Grade 2 Follicular Lymphoma", "Contiguous Stage II Grade 3 Follicular Lymphoma", "Contiguous Stage II Mantle Cell Lymphoma", "Contiguous Stage II Marginal Zone Lymphoma", "Contiguous Stage II Small Lymphocytic Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Epstein-Barr Virus Infection", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Progressive Hairy Cell Leukemia, Initial Treatment", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Hairy Cell Leukemia", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage I Adult Burkitt Lymphoma", "Stage I Adult Diffuse Large Cell Lymphoma", "Stage I Adult Diffuse Mixed Cell Lymphoma", "Stage I Adult Diffuse Small Cleaved Cell Lymphoma", "Stage I Adult Hodgkin Lymphoma", "Stage I Adult Immunoblastic Large Cell Lymphoma", "Stage I Adult Lymphoblastic Lymphoma", "Stage I Adult T-cell Leukemia/Lymphoma", "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage I Grade 1 Follicular Lymphoma", "Stage I Grade 2 Follicular Lymphoma", "Stage I Grade 3 Follicular Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage I Marginal Zone Lymphoma", "Stage I Small Lymphocytic Lymphoma", "Stage IA Mycosis Fungoides/Sezary Syndrome", "Stage IB Mycosis Fungoides/Sezary Syndrome", "Stage II Adult Hodgkin Lymphoma", "Stage II Adult T-cell Leukemia/Lymphoma", "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IIA Mycosis Fungoides/Sezary Syndrome", "Stage IIB Mycosis Fungoides/Sezary Syndrome", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-cell Leukemia/Lymphoma", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Small Lymphocytic Lymphoma", "Stage IIIA Mycosis Fungoides/Sezary Syndrome", "Stage IIIB Mycosis Fungoides/Sezary Syndrome", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Small Lymphocytic Lymphoma", "Stage IVA Mycosis Fungoides/Sezary Syndrome", "Stage IVB Mycosis Fungoides/Sezary Syndrome", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Untreated Hairy Cell Leukemia", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2013-03-05", "completion_date": "2018-12-31", "has_results": true, "last_update_posted_date": "2021-09-01", "last_synced_at": "2026-11-14T09:32:28.853Z", "location_count": 3, "location_summary": "Chicago, Illinois • Boston, Massachusetts", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01805037" }, { "nct_id": "NCT03702231", "title": "Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Safety and Tolerability", "Compare SHINGRIX Vaccine Response Rates", "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)" ], "interventions": [ { "name": "Zoster Vaccine Recombinant, Adjuvanted", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 116, "start_date": "2018-12-07", "completion_date": "2023-07-12", "has_results": true, "last_update_posted_date": "2023-08-04", "last_synced_at": "2026-11-14T09:32:28.853Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03702231" }, { "nct_id": "NCT01520922", "title": "Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Leukaemia, Lymphocytic, Chronic" ], "interventions": [ { "name": "Ofatumumab", "type": "BIOLOGICAL" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2012-03", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-01-19", "last_synced_at": "2026-11-14T09:32:28.853Z", "location_count": 6, "location_summary": "Tuscon, Arizona • Aurora, Colorado • Fort Myers, Florida + 3 more", "locations": [ { "city": "Tuscon", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01520922" }, { "nct_id": "NCT03670966", "title": "211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia in Remission", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Acute Myeloid Leukemia in Remission", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome With Excess Blasts", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Recurrent Mixed Phenotype Acute Leukemia", "Refractory Mixed Phenotype Acute Leukemia", "Hematopoietic and Lymphoid Cell Neoplasm" ], "interventions": [ { "name": "Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Recombinant Granulocyte Colony-Stimulating Factor", "type": "BIOLOGICAL" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2019-07-10", "completion_date": "2029-10-20", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-11-14T09:32:28.853Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03670966" }, { "nct_id": "NCT00088543", "title": "Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Myelogenous Leukemia (AML)", "Acute Lymphocytic Leukemia (ALL)", "Graft vs. Host Disease (GvHD)" ], "interventions": [ { "name": "Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 60, "start_date": "2004-03", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2015-03-18", "last_synced_at": "2026-11-14T09:32:28.853Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00088543" }, { "nct_id": "NCT05871008", "title": "Integrated Actionable Aging Assessment for Cancer Patients Pilot", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Hodgkin Lymphoma", "Kidney Cancer", "Leukemia", "Lymphoid Leukemia", "Multiple Myeloma", "Myeloid Leukemia", "Monocytic Leukemia", "Prostate Cancer", "Bladder Cancer" ], "interventions": [ { "name": "Assessment tool IA3-CP with SDoH", "type": "OTHER" }, { "name": "Assessment tool IA3-CP without SDoH", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": "111 Years", "sex": "ALL", "summary": "65 Years to 111 Years" }, "enrollment_count": 35, "start_date": "2024-03-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-14T09:32:28.853Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05871008" }, { "nct_id": "NCT00068315", "title": "Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hematopoietic/Lymphoid Cancer", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Splenic Marginal Zone Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2003-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-11-14T09:32:28.853Z", "location_count": 7, "location_summary": "Canton, Ohio • Cleveland, Ohio • Middleburg Heights, Ohio + 3 more", "locations": [ { "city": "Canton", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Middleburg Heights", "state": "Ohio" }, { "city": "Orange", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068315" }, { "nct_id": "NCT06588478", "title": "A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loxo Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 249, "start_date": "2025-01-03", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-14T09:32:28.853Z", "location_count": 20, "location_summary": "Chandler, Arizona • Duarte, California • Irvine, California + 16 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06588478" }, { "nct_id": "NCT06551584", "title": "Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoid Leukemia", "Mixed Phenotype Acute Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "ORCA-T", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2025-12-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-11-14T09:32:28.853Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06551584" } ] }